Weisz L - Search Results

1

Transactivation of the EGR1 gene contributes to mutant p53 gain of function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Weisz L, et al. Cancer Res. 2004 Nov 15;64(22):8318-27. doi: 10.1158/0008-5472.CAN-04-1145. Cancer Res. 2004. Retraction in: Cancer Res. 2019 Apr 15;79(8):2085. doi: 10.1158/0008-5472.CAN-19-0560 PMID: 15548700 Retracted.

2

Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.

Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM, Krammer PH, Rotter V, Oren M. Zalcenstein A, et al. Among authors: weisz l. Oncogene. 2003 Aug 28;22(36):5667-76. doi: 10.1038/sj.onc.1206724. Oncogene. 2003. PMID: 12944915

3

Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.

Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, Rotter V, Blandino G, Oren M. Weisz L, et al. Cancer Res. 2007 Mar 15;67(6):2396-401. doi: 10.1158/0008-5472.CAN-06-2425. Cancer Res. 2007. PMID: 17363555

4

Modulation of the vitamin D3 response by cancer-associated mutant p53.

Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, Blandino G, Simon I, Oren M, Rotter V. Stambolsky P, et al. Among authors: weisz l. Cancer Cell. 2010 Mar 16;17(3):273-85. doi: 10.1016/j.ccr.2009.11.025. Cancer Cell. 2010. PMID: 20227041 Free PMC article.

5

Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.

Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Zalcenstein A, et al. Among authors: weisz l. Oncogene. 2006 Jan 19;25(3):359-69. doi: 10.1038/sj.onc.1209061. Oncogene. 2006. PMID: 16170349

6

Regulation of AIF expression by p53.

Stambolsky P, Weisz L, Shats I, Klein Y, Goldfinger N, Oren M, Rotter V. Stambolsky P, et al. Among authors: weisz l. Cell Death Differ. 2006 Dec;13(12):2140-9. doi: 10.1038/sj.cdd.4401965. Epub 2006 May 26. Cell Death Differ. 2006. PMID: 16729031

7

Transcription regulation by mutant p53.

Weisz L, Oren M, Rotter V. Weisz L, et al. Oncogene. 2007 Apr 2;26(15):2202-11. doi: 10.1038/sj.onc.1210294. Oncogene. 2007. PMID: 17401429 Review.

8

Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect.

Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, Weisz L, Kogan I, Cohen M, Shatz M, Madar S, Kalo E, Goldfinger N, Yuan J, Ron S, MacKenzie K, Eden A, Rotter V. Milyavsky M, et al. Among authors: weisz l. Cancer Cell. 2007 Feb;11(2):133-46. doi: 10.1016/j.ccr.2006.11.022. Cancer Cell. 2007. PMID: 17292825 Free article.

9

Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, Stambolsky P, Henis YI, Rotter V. Kalo E, et al. Among authors: weisz l. Mol Cell Biol. 2007 Dec;27(23):8228-42. doi: 10.1128/MCB.00374-07. Epub 2007 Sep 17. Mol Cell Biol. 2007. PMID: 17875924 Free PMC article.

10

Retraction: Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function.

Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, Rotter V. Weisz L, et al. Cancer Res. 2019 Apr 15;79(8):2085. doi: 10.1158/0008-5472.CAN-19-0560. Cancer Res. 2019. PMID: 30987981 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters